Physician profile
Anna C Liu
NPI 1417143991
$850.52
in general payments reported to CMS, 2019-2025
12 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.87 · 2020: $76.33 · 2021: $163 · 2022: $50.41 · 2023: $132 · 2024: $261 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $280.50 | 2022-2025 | Farxiga |
| Viiv Healthcare Company | $99.52 | 2023-2024 | Apretude |
| Adlon Therapeutics L.P. | $92.85 | 2021 | |
| Lilly USA, LLC | $89.94 | 2021-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $58.95 | 2020 | |
| Abbvie INC. | $44.66 | 2021-2022 | |
| Hologic Sales and Service, LLC | $43.39 | 2021-2025 | Aptima |
| Madrigal Pharmaceuticals | $37.77 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $36.74 | 2024 | Invega Sustenna |
| Glaxosmithkline, LLC. | $24.87 | 2019 | |
| Organon LLC | $23.95 | 2023 | Nexplanon |
| Amarin Pharma, INC. | $17.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.